NFL Biosciences SA (EPA:ALNFL)

Market Cap	12.51M
Revenue (ttm)	46.00
Net Income (ttm)	-2.08M
Shares Out	10.17M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,307
Average Volume	78,139
Open	1.268
Previous Close	1.268
Day's Range	1.206 - 1.278
52-Week Range	1.180 - 3.280
Beta	1.44
RSI	36.13
Earnings Date	Mar 28, 2025

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers. Its pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; NFL-201, a drug candidate for cannabis addiction currently in preclinical stage; and NFL-301, a drug candidate for reducing alcohol consumption, currently under in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 5
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNFL

Financial Performance

In 2024, NFL Biosciences's revenue was 46, a decrease of -99.98% compared to the previous year's 200,011. Losses were -2.08 million, -44.44% less than in 2023.